Table of Contents

• What is D,L-Lysine Acetylsalicylate?
• Medical Condition Treated
• Administration and Dosage
• Comparison with Oral Aspirin
• Study Objectives and Outcomes
• Potential Benefits

What is D,L-Lysine Acetylsalicylate?

D,L-Lysine Acetylsalicylate, also known as BAY81-8781, is an intravenous (IV) form of aspirin. It is a medication being studied for its potential benefits in treating certain heart conditions^[1]. This drug is essentially aspirin that can be administered directly into a vein, allowing for potentially faster and more effective treatment in emergency situations.

Medical Condition Treated

The primary medical condition that D,L-Lysine Acetylsalicylate is being investigated for is Acute Coronary Syndrome (ACS)^[1]. ACS is a term used to describe a range of conditions associated with sudden, reduced blood flow to the heart. This includes conditions such as:

• Unstable angina (chest pain that occurs at rest or with minimal exertion)
• Non-ST elevation myocardial infarction (a type of heart attack)
• ST elevation myocardial infarction (another type of heart attack)

Administration and Dosage

D,L-Lysine Acetylsalicylate is administered intravenously, meaning it is injected directly into a vein. The clinical trial investigated two different dosages^[1]:

1. 500 mg IV: A single intravenous dose of aspirin at 500 mg, given as a bolus infusion injection in approximately 30 seconds through the vein on Day 1.
2. 250 mg IV: A single intravenous dose of aspirin at 250 mg, also given as a bolus infusion injection in approximately 30 seconds through the vein on Day 1.

Comparison with Oral Aspirin

The study also included a comparison group that received a traditional oral form of aspirin^[1]:

• 300 mg Tablet: A single oral dose of aspirin tablet at a dose of 300 mg on Day 1.

Study Objectives and Outcomes

The main objective of the study was to investigate whether intravenous administration of D,L-Lysine Acetylsalicylate (250 mg and 500 mg) is superior to oral treatment with 300 mg aspirin tablets in patients with Acute Coronary Syndrome^[1]. The study measured several outcomes to assess the effectiveness of the treatment:

• Primary Outcome: Concentration of Thromboxane B2 (TXB2) at 5 minutes post-dose. TXB2 is a substance that promotes blood clotting, and its reduction indicates the effectiveness of the aspirin.
• Secondary Outcomes:
  • TXB2 concentration at 20 minutes post-dose
  • Platelet Aggregation Inhibition (PAI) at 5 and 20 minutes after drug administration. PAI measures how well the drug prevents platelets from clumping together, which is important in preventing blood clots.
  • Serum concentration of prostacyclin metabolite at 5 and 20 minutes post-dose. Prostacyclin helps prevent blood clots and dilates blood vessels.
  • Incidence of cardiovascular death, stroke, and myocardial infarction up to 30 days after drug administration
  • Incidence of deaths from all causes, cardiovascular deaths, myocardial re/infarctions, and ischemic strokes within 24 hours, 7 days, and 30 days after drug administration

Potential Benefits

While the full results of the study are not provided in the given information, the potential benefits of D,L-Lysine Acetylsalicylate (intravenous aspirin) in treating Acute Coronary Syndrome may include^[1]:

• Faster action: Intravenous administration may allow the drug to start working more quickly than oral tablets.
• More predictable absorption: By bypassing the digestive system, IV administration ensures that the full dose reaches the bloodstream.
• Useful in emergency situations: For patients who cannot take oral medications (e.g., unconscious patients or those experiencing severe nausea), IV administration provides an alternative method of delivering this important medication.
• Potentially more effective at preventing complications: By acting more quickly, it may be more effective at preventing serious complications of ACS such as heart attacks or strokes.